Suspicion arises over sudden termination of Phase III clinical trials with clevudine
Published: 2009-04-28 07:00:00
Updated: 2009-04-28 07:00:00
Bukwang Pharm has questioned on Pharmasset’s April 20 announcement to voluntarily halt its Phase III QUASH studies of clevudine for the treatment of chronic hepatitis B (HBV) infection, amid reports that the two sides promised to have a meeting soon.
Under license from Bukwang, Pharmasset was ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
